Moreover, the targeting of JAK2/STAT3 triggers CLL cell time- and dose-dependent apoptosis, the inhibition of Lyn through the re-activation of the phosphatase SHP-1, and enhances ibrutinib activity partially overcoming BMSC support. The gene discussed is JAK2; the disease is B-cell chronic lymphocytic leukemia.